Elixirgen Therapeutics successfully concludes pre-IND meeting with FDA
BALTIMORE, May 30, 2017 – Elixirgen Therapeutics has successfully concluded its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for inherited bone marrow failure syndromes (IBMFS), including Dyskeratosis Congenita (DC) and Fanconi Anemia (FA). IBMFS such as DC and FA are rare genetic disorders known for their aplastic anemia, which hinders blood cell […]
Elixirgen Therapeutics successfully concludes pre-IND meeting with FDA Read More »